Cardiol TherapeuticsSTU:CT9 +0.23%38 EBIT per Share is €-0.24 as of Mar. 2026. GuruFocus rates STU:CT9 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, Cardiol Therapeutics ranks better than 62.55% on this metric.
Cardiol Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.24.
During the past 3 years, the average EBIT per Share Growth Rate was 15.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cardiol Therapeutics's EBIT per Share or its related term are showing as below:
STU:CT9'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -114.7 Med: 3.05 Max: 15.8
Current: 15.8
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Cardiol Therapeutics was 15.80% per year. The lowest was -114.70% per year. And the median was 3.05% per year.
STU:CT9's 3-Year EBIT Growth Rate is ranked better than 62.55% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs STU:CT9: 15.80
Cardiol Therapeutics (STU:CT9) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cardiol Therapeutics EBIT per Share Related Terms
Cardiol Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (STU:CT9) has a EBIT per Share of €-0.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #303 out of 809 companies in the Drug Manufacturers industry, placing it in the top 37.5%.
Is Cardiol Therapeutics' EBIT per Share too high?
Cardiol Therapeutics' current EBIT per Share is €-0.24. Based on the distribution chart, Cardiol Therapeutics ranks #303 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cardiol Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #303 out of 809 companies for EBIT per Share. This puts Cardiol Therapeutics in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current EBIT per Share is €-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current EBIT per Share of €-0.24. The current EBIT per Share is €-0.24. Cardiol Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current EBIT per Share is €-0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
38GF Score
Get the complete analysis for STU:CT9
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CT9 has been successfully added to your 
